$BMY Headlines Bristol-Myers guidance tops estimates

New Post Public Reply Private Reply Replies (0) Message Board

Jan 29, 2016 at 12:54 PM

$BMY Headlines

Bristol-Myers guidance tops estimates 7:06 a.m. Jan. 28, 2016 - MarketWatch.com
Apple, Amazon headline crucial week for Wall Street quarterly results 9:30 a.m. Jan. 23, 2016 - Wallace Witkowski
10 biotech stocks to buy at ‘silly’ cheap prices 10:10 a.m. Jan. 16, 2016 - Michael Brush
Shire agrees to buy Baxalta for $32 billion 8:49 a.m. Jan. 11, 2016 - MarketWatch.com
GlaxoSmithKline buys Bristol-Myers HIV assets 4:33 a.m. Dec. 18, 2015 - MarketWatch.com
GlaxoSmithKline to buy Bristol-Myers's HIV assets 3:21 a.m. Dec. 18, 2015 - MarketWatch.com
Samsung's bet on biotech is test for heir apparent 5:37 p.m. Dec. 17, 2015 - MarketWatch.com
5 stocks to watch 12:18 p.m. Dec. 16, 2015 - The Trading Deck
Charting the S&P 500’s impending golden cross 11:05 a.m. Dec. 9, 2015 - Michael Ashbaugh
S&P 500 will creep up to 2,200 in 2016, J.P. Morgan says 7:01 a.m. Dec. 7, 2015 - Sara Sjolin
Bristol-Myers Squibb upgraded to buy from neutral at Guggenheim 12:04 p.m. Dec. 2, 2015 - Tomi Kilgore
Merck, J&J and Lilly shares climb after upgrades at Barclays 10:14 a.m. Dec. 1, 2015 - Tomi Kilgore
Bristol-Myers Squibb stock price target raised to $70 from $55 at Barclays 9:44 a.m. Dec. 1, 2015 - Tomi Kilgore
Bristol-Myers to buy Cardioxyl Pharmaceuticals 8:11 a.m. Nov. 2, 2015 - Ciara Linnane
Merck eyes acquisitions amid slump in biotech 12:12 p.m. Oct. 27, 2015 - MarketWatch.com
Merck profit more than doubles, raises outlook 7:06 a.m. Oct. 27, 2015 - MarketWatch.com
Bristol-Myers shares up 3.6% in premarket trade 6:20 a.m. Oct. 27, 2015 - Ciara Linnane
Bristol-Myers revenue buoyed by cancer drug 6:02 a.m. Oct. 27, 2015 - MarketWatch.com
Apple clashes with energy to save earnings season 7:00 a.m. Oct. 25, 2015 - Wallace Witkowski
Five Prime's stock rockets 57% premarket after licensing deal with Bristol-Myers 7:19 a.m. Oct. 15, 2015 - Tomi Kilgore

Healthcare ratings roundup 50 min ago - Seeking Alpha
Bristol-Myers Squibb (BMY) Earnings Report: Q4 2015 Conference Call Transcript 7:45 a.m. Today - TheStreet.com
Bristol-Myers Squibb's (BMY) CEO Giovanni Caforio on Q4 2015 Results - Earnings Call Transcript 4:40 p.m. Jan. 28, 2016 - Seeking Alpha
'The Market Doesn't Know Where It's Headed' 4:02 p.m. Jan. 28, 2016 - TheStreet.com
Stocks Back Near Highs in Unsettled Session 2:23 p.m. Jan. 28, 2016 - TheStreet.com
Bristol-Myers Revenue Rises 1% 1:12 p.m. Jan. 28, 2016 - The Wall Street Journal Interactive Edition
Expanded uses of Bristol-Myers Squibb's HCV med Daklinza cleared in Europe 12:59 p.m. Jan. 28, 2016 - Seeking Alpha
Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish 11:20 a.m. Jan. 28, 2016 - benzinga.com
Stocks Back to Positive as Energy Trumps Health Care 11:16 a.m. Jan. 28, 2016 - TheStreet.com
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Unusual Social Activity Stock 10:53 a.m. Jan. 28, 2016 - TheStreet.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance 10:12 a.m. Jan. 28, 2016 - Zacks.com
Bristol-Myers' Opdivo successful in late-stage study in head and neck cancer 9:43 a.m. Jan. 28, 2016 - Seeking Alpha
Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues 8:13 a.m. Jan. 28, 2016 - Zacks.com
Short Sellers Become More Selective on Major Pharma 7:59 a.m. Jan. 28, 2016 - 247WallSt.com
Bristol-Myers Q4 product sales up 19%; non-GAAP EPS down 17%; net loss of $138M 7:25 a.m. Jan. 28, 2016 - Seeking Alpha
Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance 6:54 a.m. Jan. 28, 2016 - benzinga.com
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Post-Market Leader Stock 5:55 p.m. Jan. 27, 2016 - TheStreet.com
Notable earnings before Thursday’s open 5:30 p.m. Jan. 27, 2016 - Seeking Alpha
Bristol-Myers Squibb (BMY) Closed Down as Analysts Expect Earnings Decline 4:06 p.m. Jan. 27, 2016 - TheStreet.com
Lilly’s Valuation Multiples Have Followed the Industry’s Trend 1:20 p.m. Jan. 22, 2016 - MarketRealist.com

Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion forInvestigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy 7:48 a.m. Today - BusinessWire - BZX
European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV 12:41 p.m. Jan. 28, 2016 - BusinessWire - BZX
CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early 6:59 a.m. Jan. 28, 2016 - BusinessWire - BZX
Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer 7:02 a.m. Jan. 27, 2016 - BusinessWire - BZX
Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma 8:00 a.m. Jan. 25, 2016 - BusinessWire - BZX
REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 6:59 a.m. Jan. 25, 2016 - BusinessWire - BZX
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 6:36 p.m. Jan. 23, 2016 - BusinessWire - BZX
Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 4:52 p.m. Jan. 20, 2016 - PR Newswire - PRF
Cancer Immunotherapy: Payer Insight 3:41 p.m. Jan. 20, 2016 - PR Newswire - PRF
CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone 8:01 a.m. Jan. 20, 2016 - GlobeNewswire
MOLOGEN AG: First combination trial with MGN1703and a checkpoint inhibitor in collaboration with MD Anderson 4:09 a.m. Jan. 19, 2016 - BusinessWire - BZX
SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents 8:02 a.m. Jan. 11, 2016 - Marketwired
Dual Therapeutics Announces Oncology Strategic Collaboration With Bristol-Myers Squibb 8:00 a.m. Jan. 8, 2016 - Marketwired
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3:39 p.m. Jan. 7, 2016 - PR Newswire - PRF
Insights on Immuno-Oncology Drug Development and the Field’s True Potential 6:00 a.m. Jan. 6, 2016 - BusinessWire - BZX
Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020 4:39 p.m. Jan. 5, 2016 - PR Newswire - PRF
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 10:00 a.m. Jan. 5, 2016 - BusinessWire - BZX
Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Outlook Stable 2:17 p.m. Dec. 23, 2015 - BusinessWire - BZX
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin)in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma 8:00 a.m. Dec. 23, 2015 - BusinessWire - BZX
Global Psoriatic Arthritis Market 2015-2019 4:47 p.m. Dec. 22, 2015 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....